Aptamer Group Ltd, a York, UK-based biotech company, closed a $2.2m Series A funding round.
Backers included Netherlands-based biopharmaceutical investment company Meneldor and other overseas investors.
The company intends to use the funds to create ten new positions in technical, sales and administration roles and to drive forward its pre-clinical discovery programs involving the development of aptamer drug conjugates (ApDCs).
Founded in 2008 by Chief Executive Officer, Dr Arron Tolley and Chief Technical Officer, Dr David Bunka, Aptamer Group specializes in identification, development and characterization of nucleic acid aptamers – a synthetic alternative to antibodies – which are becoming alternatives to traditional antibody approaches.
In details, the company provides high throughput aptamer screening services (Aptasol), biomarker discovery and validation tools (Aptasort), diagnostics devices / reagents (Aptadx) and develops therapeutic lead compounds (Aptarx).
The company has a team of 16 serving a global customer base of more than 50 organizations.
Aptamer recently added an office in Boston (United States) where the aptamer market is growing rapidly.